DRL's subsidiary receives FDA nod for anti-psoriasis cream

Dr Reddy's Laboratories Ltd today said its US subsidiary Promius Pharma, LLC, received fifth consecutive and final approval for its speciality drug Impoyz (clobetasol propionate) cream, 0.025 per cent, from the US Food and Drug Administration.

A statement from the drug maker said it is a first-cycle NDA (new drug application) approval for the Proprietary Products Group, a substantial milestone within the pharmaceutical industry.

Impoyz (clobetasol propionate) cream, 0.025 per cent, is a high-potency topical steroid approved for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older.

This approval is another example of the deep and broad capabilities within the Proprietary Products business unit at Dr Reddy's. The organisation has achieved several milestones within drug, device and formulation research and development for novel therapies, it said.
 

Anil Namboodiripad, Senior Vice President, Proprietary Products and President Promius Pharma, said they are looking forward to working with their partner, Encore Dermatology, to commercialise.

"The fifth consecutive first cycle NDA approval represents Dr Reddy's long-term commitment to building an organisation that delivers innovative medical solutions. We are looking forward to working with our partner, Encore Dermatology, to bring this novel treatment to providers and their patients," Namboodiripad said.

"Encore is excited about adding another great product to our portfolio and looking forward to the opportunity to commercialise a new product for the treatment of mild to moderate psoriasis as well as broadening our portfolio outside of atopic dermatitis and acne," said Robert Moccia, CEO of Encore Dermatology Inc, said.

The most common side effect of Impoyz cream includes discolouration of the treated site, the release said.

Psoriasis is a serious medical condition affecting approximately 7.5 million people in the United States. Impoyz, formerly referred to as DFD-06, had been recently licensed to Encore Dermatology Inc for the commercialisation of the product in the United States, it added.